(Q40310290)

19 September 2017

title

Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine (English)

1 reference

19 September 2017

Jean-Marie Brusq

1

1 reference

19 September 2017

Nicolas Ancellin

2

1 reference

19 September 2017

Pascal Grondin

3

1 reference

19 September 2017

Raphaelle Guillard

4

1 reference

19 September 2017

Sandrine Martin

5

1 reference

19 September 2017

Yannick Saintillan

6

1 reference

19 September 2017

Marc Issandou

7

1 reference

19 September 2017

publication date

28 February 2006

1 reference

Journal of Lipid Research

19 September 2017

published in

1 reference

19 September 2017

volume

47

1 reference

19 September 2017

issue

6

1 reference

19 September 2017

page(s)

1281-1288

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

Pharmacotherapy for dyslipidaemia – current therapies and future agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with p

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

New lipid-lowering agents acting on LDL receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

SCAP ligands are potent new lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

The AMP-activated protein kinase--fuel gauge of the mammalian cell?

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

AICAR, an activator of AMP-activated protein kinase, down-regulates the insulin receptor expression in HepG2 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

AMP kinase activation with AICAR further increases fatty acid oxidation and blunts triacylglycerol hydrolysis in contracting rat soleus muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

Effects of stimulation of AMP-activated protein kinase on insulin-like growth factor 1- and epidermal growth factor-dependent extracellular signal-regulated kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600020-JLR200

10.1194/JLR.M600020-JLR200

21 January 2018

Identifiers

DOI

1 reference

19 September 2017

1 reference